Compare YSXT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ANVS |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 111.3M |
| IPO Year | 2024 | 2020 |
| Metric | YSXT | ANVS |
|---|---|---|
| Price | $1.15 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 544.4K | 430.4K |
| Earning Date | 02-03-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.96 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $78,350,172.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.47 | ★ N/A |
| Revenue Growth | ★ 18.45 | N/A |
| 52 Week Low | $1.03 | $1.11 |
| 52 Week High | $9.96 | $5.50 |
| Indicator | YSXT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 33.27 |
| Support Level | $1.12 | $2.29 |
| Resistance Level | $1.39 | $2.65 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.09 | 10.39 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.